1405 ALISPORIVIR PLUS RIBAVIRIN IS HIGHLY EFFECTIVE AS INTERFERON-FREE OR INTERFERON-ADD-ON REGIMEN IN PREVIOUSLY UNTREATED HCV-GT2 OR GT3 PATIENTS: SVR12 RESULTS FROM VITAL-1 PHASE 2B STUDY
Jean–Michel Pawlotsky(Université Paris-Est Créteil), N.V. Naoumov, Teerha Piratvisuth(Prince of Songkla University), Robert Flisiak(Medical University of Białystok), Wan‐Long Chuang(Kaohsiung Medical University), GR Foster, Heiner Wedemeyer(Medizinische Hochschule Hannover), J. Rasenack(University of Freiburg), S.K. Sarin, Cheng‐Yuan Peng(China Medical University), W.M. Zhang
Cited by 42
Related Papers
Consensus Proposals for a Unified System of Nomenclature of Hepatitis C Virus Genotypes *
|Hepatology|2005|1.5k
Mitotic and G <sub>2</sub> Checkpoint Control: Regulation of 14-3-3 Protein Binding by Phosphorylation of Cdc25C on Serine-216
|Science|1997|1.3k
ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
|New England Journal of Medicine|2014|877
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2016|817
SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma
|Journal of Clinical Oncology|2018|653